Avecho Biotechnology Limited filed its Annual on Mar 15, 2023 for the period ending Dec 31, 2022. In this report its auditor, Grant Thornton, gave an unqualified opinion expressing doubt that the company can continue as a going concern.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.004 AUD | 0.00% | 0.00% | +14.29% |
Mar. 25 | Avecho Biotechnology Begins Patient Recruitment for Phase Three Anti-Insomnia Drug Trial | MT |
Mar. 14 | Avecho to Push Forward with Phase III Trial of Anti-Insomnia Drug | MT |
1st Jan change | Capi. | |
---|---|---|
+14.29% | 8.27M | |
+1.51% | 42.75B | |
+48.71% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- AVE Stock
- News Avecho Biotechnology Limited
- Avecho Biotechnology Limited Auditor Raises 'Going Concern' Doubt